Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean COVID-19 Contenders Still Racing Toward Finish Line

Oral Niclosamide Moves To Pivotal Stage

Executive Summary

Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.

You may also be interested in...



COVID-19 DNA Vaccine Halt Another Blow To AnGes

AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.

Dong-A ST Faces New Wave Of Change As It Challenges Norms

Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.

How KIMCo Is Orchestrating Korean Pharma Collaborations

KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel